This is the third edition of this guideline. It replaces The Management of Gestational Trophoblastic Neoplasia, which was published in 2004 which, in turn, replaced The Management of Gestational Trophoblastic Disease, issued in April 1999 as Guideline No. 18.
Gestational trophoblastic disease (GTD) forms a group of disorders spanning the conditions of complete and partial molar pregnancies through to the malignant conditions of invasive mole, choriocarcinoma and the very rare placental site trophoblastic tumour (PSTT). There are reports of neoplastic transformation of atypical placental site nodules to placental site trophoblastic tumour.
If there is any evidence of persistence of GTD, most commonly defined as a persistent elevation of beta human chorionic gonadotrophin (βhCG), the condition is referred to as gestational trophoblastic neoplasia (GTN).
The purpose of this guideline is to describe the presentation, management, treatment and follow-up of GTD and GTN. It also provides advice on future pregnancy outcomes and the use of contraception.
This guideline is can be downloaded as a pdf using the link below.
The revision for this Guideline will not begin until mid-end 2015 and be published early 2017.